Christopher Lee

Dr. Christopher Lee


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2006 in Cancer
Verified
Journal Article
Open access
PDF file
OMO. Kenneth Macdonald
O. Kenneth Macdonald
CLChristopher Lee
Christopher Lee
JTJonathan David Tward
Jonathan David Tward
CCCraig D. Chappel
Craig D. Chappel
DGDavid K. Gaffney
David K. Gaffney
BACKGROUND.: Malignant phyllodes tumor is a rare and potentially aggressive breast neoplasm. Little information is available regarding the optimal management of these lesions and rarer still are data regarding survival. The current study used a large population database to determine prognostic factors that predict cause‐specific survival (CSS).METHODS.: Data were obtained from the Surveillance, Epidemiology, and End Results Program (SEER) for the years 1983–2002. Women receiving resection for primary nonmetastatic malignant phyllodes tumor of the breast were included (n= 821). Analyses of patient, pathologic, and treatment characteristics were performed using univariate and multivariate Cox regression analyses for the CSS endpoint.RESULTS.: With a median follow‐up of 5.7 years, CSS was 91%, 89%, and 89%, at 5, 10, and 15 years, respectively. Mastectomy was performed in 428 women (52%) and wide excision or lumpectomy in 393 (48%). Women undergoing mastectomy were significantly older (P= .004) and had larger tumors (P= .009). Wide excision was associated with equivalent or improved CSS relative to mastectomy on univariate and multivariate analyses. Older age predicted for cause‐specific mortality on multivariate analysis. Adjuvant radiotherapy (RT) predicted for worse CSS when implemented compared with surgery alone.CONCLUSIONS.: Mastectomy was not found to provide a benefit in CSS compared with wide excision in malignant phyllodes tumor of the breast. Women undergoing wide excision had at the minimum similar cancer‐specific mortality compared with those who received mastectomy. The role of adjuvant RT is uncertain and requires further investigation. Cancer 2006. © 2006 American Cancer Society.

9 February 2011 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
BABenjamin J. Arthurs
Benjamin J. Arthurs
RFRobert K. Fairbanks
Robert K. Fairbanks
JDJohn J. Demakas
John J. Demakas
WLWayne T. Lamoreaux
Wayne T. Lamoreaux
NGNeil A. Giddings
Neil A. Giddings
CLChristopher Lee
Christopher Lee

1 January 2006 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CLChristopher Lee
Christopher Lee
CFChrista B. Fuhrman
Christa B. Fuhrman
VPVicente Planelles
Vicente Planelles
MPMorgan R. Peltier
Morgan R. Peltier
DGDavid K. Gaffney
David K. Gaffney
KZKaren A. Zempolich
Karen A. Zempolich
Purpose: The phosphatidylinositol 3-kinase (PI3K) catalytic subunit is amplified in cervical cancers, implicating PI3K in cervical carcinogenesis. We evaluated the radiosensitizing effect of PI3K inhibition by LY294002 on clonogenic survival, growth characteristics, and gene expression in cervical cancer cell lines (HeLa and CaSki). Experimental Design: Cervical cancer cells were treated separately and concurrently with the PI3K inhibitor LY294002 (10 μmol/L) and radiation (2 Gy) with serial analysis of cell count, apoptosis, and flow cytometry. PI3K inhibition was assessed by protein analysis of phosphorylated Akt. Clonogenic assays were done with varying doses of radiation and LY294002 and varied time points of administration of LY294002 proximate to the radiation dose. Surviving fractions and dose modification factors (DMF) were calculated. Each experiment was done in triplicate and analyzed using ANOVA regression analysis and Dunnett's t Test. Microarray gene expression analysis was done on the HeLa cell line. Results: PI3K inhibition with LY294002 alone did not decrease cell survival. However, treatment with LY294002 significantly radiosensitized HeLa and CaSki cell lines with DMFs (1 log cell kill) of 1.95 and 1.37, respectively. Compared with post-irradiation, pretreatment produced more radiosensitization (P < 0.0001). DMFs were 2.2, 2.0, 2.0, and 1.2 for LY294002 added at 6, 2, and 0.5 hours before irradiation and 6 hours after irradiation, respectively. LY294002 pretreatment in irradiated HeLa cells led to altered gene expression. Conclusions: Although LY294002 alone did not produce cytotoxic effects, PI3K inhibition with LY294002 produced significant radiosensitization, showed significant time-dependent effects, increased apoptosis, and altered gene expression. These findings support future investigation of PI3K inhibitors in combination with radiation therapy for carcinoma of the cervix.

25 January 2006 in JAMA
Verified
Journal Article
Open access
PDF file
CLChristopher Lee
Christopher Lee
ASAniko Szabo
Aniko Szabo
DSDennis C. Shrieve
Dennis C. Shrieve
OMO. Kenneth Macdonald
O. Kenneth Macdonald
DGDavid K. Gaffney
David K. Gaffney
Endometrial cancer remains the most common gynecological malignancy in the United States; however, the optimal adjuvant treatment for stage I endometrial adenocarcinoma remains elusive despite published results from randomized trials. Recent publications have revealed 5-year overall survival rates of 80% to 90% for women with stage I disease who have received total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) and adjuvant radiation therapy (RT) based on clinical and pathological characteristics.1-7 Despite these encouraging results, the specific subgroup of patients with American Joint Committee on Cancer stage IC (>50% myometrial invasion) and high-grade disease (grade 3 or 4) are known to have relatively poorer outcomes with higher rates of both local and distant relapses.8

1 August 2009 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
OMO Kenneth Macdonald
O Kenneth Macdonald
JCJergin Chen
Jergin Chen
MDMark Dodson
Mark Dodson
CLChristopher Lee
Christopher Lee
DGDavid K. Gaffney
David K. Gaffney
Lymph node (LN) metastasis portends a poor outcome in women with carcinoma of the uterine cervix. We queried a large database to analyze the importance of number of positive LN and histology in relation to survival after radical hysterectomy and lymphadenectomy. Data were collected from the Surveillance, Epidemiology, and End Results Program on women who had primary surgery for the years 1988 to 2003 (n = 4559). Statistical analyses were performed using conventional methods. The median number of LNs examined per patient has significantly declined in recent years (P = 0.003). The 5-year rates of cause specific and overall survival were 94% and 91%, 76% and 69%, 62% and 58%, and 41% and 35%, for 0, 1 to 2, 3 to 9 and ≥10 positive LNs, respectively. Pathologic LN involvement was associated with higher grade, higher stage, larger tumor size, and squamous cell histology. Predictors for both cause specific and overall survival on multivariate analysis included number of involved LN, histology, tumor grade, tumor size, disease stage, and pelvis or paraaortic lymphatic involvement. Adenocarcinoma histology independently predicted for a more aggressive phenotype, particularly in women with LN involvement. The number of LNs examined did not independently predict for survival when adjusted for patient and disease characteristics, providing context for the investigation of sentinel node biopsy or other sampling methods. LN positive disease in carcinoma of the cervix predicts a prognosis that is inversely related to the number of involved nodes. Tumor grade, size, and FIGO stage were associated with increasing risk for lymph node metastases.

1 November 2005 in Gynecologic Oncology
Verified
Journal Article
Closed access
CLChristopher Lee
Christopher Lee
DSDennis C. Shrieve
Dennis C. Shrieve
KZKaren A. Zempolich
Karen A. Zempolich
RLR. Jeffrey Lee
R. Jeffrey Lee
EHElizabeth Hammond
Elizabeth Hammond
DGDavid K. Gaffney
David K. Gaffney